Chlorpromazine Injectable Solution Suppliers & Bulk Manufacturers
Available Forms: Injectable Solution (IM/IV)
Available Strengths: 25 mg/mL
Reference Brands: Largactil® (EU); Thorazine®(US)
Category:
Antipsychotropic Drugs
Chlorpromazine is a typical antipsychotic that works by blocking dopamine D2 receptors in the brain, along with histamine (H1), adrenergic (α1), and muscarinic receptors. This broad receptor activity helps reduce psychotic symptoms, agitation, nausea, and severe hiccups. The injectable form is used in emergency settings for acute psychosis, violent behavior, preoperative sedation, and intractable hiccups, offering rapid symptom control when oral administration isn’t feasible.
Chlorpromazine Injectable Solution is available in Injectable Solution (IM/IV)
and strengths such as 25 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Chlorpromazine Injectable Solution is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Chlorpromazine Injectable Solution can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Chlorpromazine injectable solution is FDA-approved in the United States for treating severe psychotic disorders, acute agitation, intractable hiccups, and as a preoperative sedative. In the EU, it is authorized in certain countries under national procedures for similar indications, primarily in emergency psychiatric and perioperative settings. Regulatory requirements include compliance with GMP standards, stability data, and safe parenteral use documentation. U.S. filings must follow strict labeling and pharmacovigilance guidelines due to risks such as hypotension and extrapyramidal symptoms. To explore dossier-ready Chlorpromazine injectable solutions and related formulations, visit Pharmatradz.com — your trusted global B2B pharma sourcing partner.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing